Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma
Status:
Withdrawn
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to develop a novel platform for allo-SCT in multiple myeloma
(MM) with the idea of maximizing anti-myeloma effect with conditioning and minimizing GvHD
(graft versus host disease). Specifically, the investigators will use the Flu/Mel
(fludarabine and melphalan) regimen. For GvHD prophylaxis, the investigators use the Hopkins
PT-Cy (post-transplant cyclophosphamide) platform with the novelty of adding tocilizumab as
both an anti-myeloma therapy and as a method to reduce GvHD. IL-6 has an important role in
promoting the growth of myeloma cells and progression of disease.